Skip to main
ATRC

AtriCure (ATRC) Stock Forecast & Price Target

AtriCure (ATRC) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AtriCure is well-positioned within the medical device industry for future growth with its innovative portfolio of products targeting surgical treatments for various cardiac conditions, including atrial fibrillation and left atrial appendage management. The company's strong financial results in the fourth quarter of 2025, with increased revenue and significant margin expansion, demonstrate its potential for sustained revenue growth and improvement in profitability. The recent success of AtriCure's clinical trials and the continued adoption of its products by physicians also support a positive outlook for the company's performance in the coming years.

Bears say

AtriCure is facing continued pressure in international markets, particularly in Germany and UK, and the company has already incorporated this into their revised 2026 outlook. However, with the potential success of their BOxX-NoAF trial and the high healthcare costs associated with post-operative Afib, there is still potential for long-term growth for AtriCure. Additionally, the company's diverse product line and focus on pain management may help to offset any short-term sales declines.

AtriCure (ATRC) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AtriCure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AtriCure (ATRC) Forecast

Analysts have given AtriCure (ATRC) a Strong Buy based on their latest research and market trends.

According to 6 analysts, AtriCure (ATRC) has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $50.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $50.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AtriCure (ATRC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.